144 Low clinical value of squamous cell carcinoma antigen in irradiated patients with advanced head and neck cancer

2003 ◽  
Vol 1 (5) ◽  
pp. S47
Author(s):  
J. Büntzel ◽  
A. Hornig ◽  
M. Glatzel ◽  
O. Micke ◽  
F. Bruns ◽  
...  
2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 15516-15516
Author(s):  
G. López-Argumedo ◽  
G. López-Vivanco ◽  
R. Fernández ◽  
I. Díaz de Corcuera ◽  
A. Sancho ◽  
...  

15516 Background: Concomitant CRT has become a standard treatment for advanced head and neck cancer. The aim of this study was to evaluate the efficacy and toxicity of concurrent CRT with D in patients (pts) with advanced squamous cell carcinoma of head and neck (SCCHN). Methods: Patients with untreated and unresectable stage III or IV (M0) squamous cell carcinoma of head and neck were included. Treatment consisted of D 20 mg/m2 weekly with concomitant radiotherapy 70 Gy (2 Gy per day, 7 weeks). Results: From September 03 to October 05, sixty-four pts with advanced SCCHN, were recruited. Gender: 61 male, 3 female. Mean age: 56.5 years old (range 42–77). ECOG PS 0/1/2: 0/57/7. Primary sites of disease: oral cavity 8, oropharynx 26, hypopharynx 15 and larynx 15. Stage III 16 pts and stage IV 48 pts. Compliance: 393 administrations of D were given, median 6, mean 6 (range 1–8). Fifty-five pts (86%) completed the radiotherapy dose planned (mean dose of RT was 66 Gy). One refused more treatment with D after first administration. Nineteen pts required supportive percutaneous gastrostomy or nasogastric tubes previously or during therapy. Grade 2/3/4 toxicity per patient: anemia 4/2/0, mucositis 21/24/0, dermatitis 21/20/0. Neither thrombopenia nor neutropenia were observed. Four pts died of aspiration pneumonia during treatment, one of gastric perforation and two of unknown causes. Fifty-six pts were evaluable for response: CR 28 (44%), PR 23 (36%), SD 2 (3%), PD 3 (5%), with an overall response rate of 80%. Median overall survival was 74.86 weeks (95% CI: 40.40–109.32) and median progression free survival was 48 weeks (95% CI: 18.80–77.20). With a median follow up of 40 weeks 34 pts (53%) were alive and 21 of them (33%) remained free of disease. Conclusions: Concurrent weekly D with conventional radiotherapy showed a high response rate. Toxicity was manageable and allowed maintaining radiotherapy administration. Taking into account poor prognostic factors of our series, survival results seem promising. No significant financial relationships to disclose.


ORL ◽  
2018 ◽  
Vol 80 (5-6) ◽  
pp. 284-289 ◽  
Author(s):  
Kitti Jantharapattana ◽  
Teerapol Kotamnivates ◽  
Siriporn Hirunpat ◽  
Roongrueng Jarumanokul

1991 ◽  
Vol 6 (4) ◽  
pp. 237-240 ◽  
Author(s):  
J.M. Bhatavdekar ◽  
D.D. Patel ◽  
H.H. Vora ◽  
D.B. Balar

Serum squamous cell carcinoma antigen (SCCAg) and protein-bound sialic acid (PBSA) were measured in 43 head and neck cancer patients and 50 controls. SCCAg and PBSA were correlated with clinical stage, histological grade, presence/absence of keratin and disease course. Patients with advanced cancer (stage III and IV) and grade III tumors had higher PBSA levels but no such difference was observed for SCCAg. Head and neck cancer patients were grouped according to the disease status i.e. a) patients who developed recurrence and b) who responded to the adjuvant therapies. There was an excellent correlation between serial serum PBSA changes and the progression of disease or the response to therapy in patients with advanced head and neck cancer.


2004 ◽  
Vol 27 (3) ◽  
pp. 180-185 ◽  
Author(s):  
Puttisak Puttawibul ◽  
Chuchart Pornpatanarak ◽  
Burapat Sangthong ◽  
Teeranut Boonpipattanapong ◽  
Sumet Peeravud ◽  
...  

1970 ◽  
Vol 17 (1) ◽  
pp. 29-35
Author(s):  
Debabrata Mitra ◽  
Kakali Choudhury ◽  
Md Abdur Rashid

Objective: The aim of this study is to compare two different palliative radiotherapy regimes - standard hypofractionated regime and split course hypofractionated regime in advanced head and neck cancer.  Methods: 60 untreated patients of advanced squamous cell carcinoma of head and neck who were treated with palliative intent were randomized into two arms: Arm A (n=30) patients received 30 Gy in 10 fractions in two weeks; Arm B (n=30) patients received 1750 cGy in 5 fractions followed by a three weeks gap and then again 1750 cGy in 5 fractons, treatment completed in 5 weeks. Result: The response was comparable in both the arms. Symptom palliation was also similar; pain relief was 76% in both arms and relief of dysphagia 73% in arm A vs 79% in arm B. Partial response rate was equivalent (69% vs 62%). Mucositis and upper GI toxicity did not show any significant difference. Patient drop out was only 1 in arm B compared to 4 in arm A. The BED10 values are 39 and 37.84 in arm A and B respectively; whereas the BED3 values are 60 and 75.8. Conclusion: We conclude that the second regime can also be used in palliative setting in some selected patients. Key words: Advanced head and neck cancer; Palliative Radiation. DOI: 10.3329/bjo.v17i1.7620 Bangladesh J Otorhinolaryngol 2011; 17(1): 29-35


2015 ◽  
Vol 135 (3) ◽  
pp. 295-301 ◽  
Author(s):  
Ryusuke Imai ◽  
Yukinori Takenaka ◽  
Toshimichi Yasui ◽  
Susumu Nakahara ◽  
Yoshifumi Yamamoto ◽  
...  

2012 ◽  
Vol 270 (7) ◽  
pp. 1981-1989 ◽  
Author(s):  
Antoine Digonnet ◽  
Marc Hamoir ◽  
Guy Andry ◽  
Vincent Vander Poorten ◽  
Missak Haigentz ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document